Financial Performance - Operating revenue for the first quarter was CNY 22,523,377.19, representing a 4.14% increase year-on-year[5] - Net profit attributable to shareholders was CNY -24,462,266.30, showing a significant decline compared to CNY -13,468,831.25 in the same period last year[5] - The company reported a net loss of CNY -136,646,152.90, compared to a loss of CNY -117,172,394.60 in the previous period[34] - The net loss for the first quarter was ¥25,042,478.69, widening the loss compared to the same period last year[27] - Basic and diluted earnings per share were both CNY -0.06, compared to CNY -0.04 in the same period last year[5] - Comprehensive loss for Q1 2021 totaled ¥31,356,753.58, compared to a loss of ¥18,397,477.63 in Q1 2020[42] - Operating profit for Q1 2021 was a loss of ¥28,253,033.96, compared to a loss of ¥15,351,539.12 in Q1 2020, indicating a worsening operational performance[41] Research and Development - Research and development expenses accounted for 109.36% of operating revenue, an increase of 43.02 percentage points from the previous year[5] - R&D expenses grew by 71.68% to ¥24,632,032.55 from ¥14,347,946.75, driven by an increase in R&D personnel[21] - Research and development expenses in Q1 2021 were ¥24,632,032.55, a significant increase of 72.06% from ¥14,347,946.75 in Q1 2020[40] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY -10,322,097.52, an improvement from CNY -59,753,722.13 in the previous year[5] - The net cash flow from operating activities was -40,581,659.77 RMB, compared to -52,590,482.40 RMB in the same quarter last year, showing an improvement[48] - Cash inflow from investment activities totaled 231,791,780.83 RMB, while cash outflow was 28,346,644.00 RMB, resulting in a net cash flow of 203,445,136.83 RMB[49] - The cash flow from investment activities showed a significant recovery, with a net cash flow of 203,445,136.83 RMB compared to a negative cash flow of -73,816,008.95 RMB in the previous year[49] Assets and Liabilities - Total assets increased by 6.52% to CNY 1,192,259,662.30 compared to the end of the previous year[5] - Non-current assets totaled CNY 402,957,729.56, compared to CNY 324,959,236.37, indicating a significant increase of about 24%[34] - Total liabilities reached CNY 186,820,747.06, up from CNY 92,729,036.15, marking an increase of around 101.5%[34] - Current liabilities rose to CNY 88,103,321.07 from CNY 80,568,899.38, reflecting an increase of approximately 18.9%[34] - Total non-current liabilities increased to CNY 98,717,425.99 from CNY 12,160,136.77, reflecting a substantial rise of approximately 711%[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,198[10] - The largest shareholder, Zhang Songgen, held 75,664,000 shares, representing 18.08% of the total shares[10] Government Subsidies - The company received government subsidies amounting to CNY 5,627,538.77, which are closely related to its normal business operations[8] - Deferred income increased by 709.77% to ¥33,598,233.33, primarily due to government subsidies received that have not yet met the conditions for recognition[20] Other Financial Metrics - Cash and cash equivalents increased by 47.40% to ¥690,435,358.03 from ¥468,402,017.87[14] - Trade financial assets decreased by 91.38% to ¥21,754,503.29 from ¥252,250,859.45, primarily due to the maturity of bank wealth management products[15] - Other receivables increased by 53.78% to ¥9,451,940.66 from ¥6,146,355.84, mainly due to an increase in rental security deposits[16] - Accounts payable surged by 112.26% to ¥10,002,276.01, reflecting an increase in payable goods and research collaboration fees[17]

Financial Performance - The company reported a total revenue of RMB 100 million for the year 2020, marking a year-on-year increase of 20%[12]. - The company's operating revenue for 2020 was ¥135,909,532.98, a decrease of 40.80% compared to the previous year[19]. - The net loss attributable to shareholders was ¥54,470,877.18, an increase of 75.95% year-on-year[21]. - The net cash flow from operating activities decreased by 380.43% to ¥-57,578,159.36 due to a decline in sales revenue[21]. - The gross profit margin for 2020 was reported at 45%, an improvement from 40% in 2019[12]. - The company achieved a net loss from non-operating income and expenses of ¥3,526,843.10 in 2020, compared to a loss of ¥3,257,904.68 in 2019[29]. - The company reported a significant increase in cash flow from financing activities, amounting to 473,110,165.69 RMB due to successful fundraising on the Sci-Tech Innovation Board[129]. - The company reported a net profit of 0 before achieving profitability, with a commitment to not reduce holdings of pre-IPO shares for 3 full accounting years post-IPO[162]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share within the next three years[12]. - The company aims to achieve a revenue growth rate of 25% in 2021, driven by new product launches and market expansion[12]. - The company is focused on advancing key technology upgrades and expanding the range of applicable indications for its products[91]. - The company is actively expanding its clinical indications for orthopedic surgical robots, with the THA (Total Hip Arthroplasty Robot) in the pre-research stage and the TKA (Total Knee Arthroplasty Robot) entering clinical validation[63]. - The company is considering potential acquisitions to bolster its market position, with a budget of $H million earmarked for this purpose[171]. - The company is exploring strategic acquisitions to bolster its market position and diversify its portfolio[192]. Research and Development - The company has allocated RMB 20 million for research and development in advanced medical technologies for 2021[12]. - Research and development expenses accounted for 54.53% of operating revenue, an increase of 20.98 percentage points from the previous year[20]. - The company has developed a collaborative R&D system with universities and research institutions, focusing on advanced product research and clinical application validation[38]. - The company has invested a total of 9,625.94 million RMB in the development of the Tianji® 2.0 spinal and trauma surgical robot, which has entered the medical device registration phase[139]. - The company plans to increase investment in R&D for orthopedic surgical robots and related consumables, leveraging partnerships with universities and hospitals to foster innovation[151]. Product Development - New product development includes a next-generation surgical robot, expected to launch in Q3 2021, with projected sales of RMB 50 million in the first year[12]. - The company’s core product, the orthopedic surgical robot, has been applied in over 100 medical institutions, completing more than 10,000 surgeries[34]. - The company has developed high-precision online calibration technology for surgical robots, with an error requirement of less than 0.5 mm[47]. - The company has created a technology for automatic synchronization and registration of intraoperative imaging, enhancing the usability of the "Tianji® 2.0" robot[53]. - The company has completed the development of core components for orthopedic surgical robots, enhancing safety and flexibility, and expanding the range of applications[69]. Financial Integrity and Governance - No non-operating fund occupation by controlling shareholders was reported, ensuring financial integrity[6]. - The company has no plans for profit distribution or capital reserve transfer in the current fiscal year[5]. - A standard unqualified audit report was issued by the accounting firm, confirming the accuracy of the financial statements[4]. - The company has established a plan to ensure compliance with commitments made by shareholders and related parties during the reporting period[159]. - The company will disclose the reasons for not proposing a cash profit distribution plan and the intended use of undistributed profits if applicable[159]. Challenges and Risks - The company experienced a significant decline in sales volume of its main product, orthopedic surgical navigation robots, due to the impact of the COVID-19 pandemic[21]. - The company faces risks related to the high technical barriers and long R&D cycles associated with new product development in the orthopedic surgical robot sector[95]. - The ongoing COVID-19 pandemic continues to pose risks to the company’s production and operational activities[106]. - The company is exposed to risks from intensified market competition, particularly from major multinational medical device companies[98]. Shareholder and Management Policies - The cash dividend policy stipulates a minimum of 80% payout for mature companies without major capital expenditures, and 40% if there are significant expenditures[157]. - The actual controller and shareholders committed to not transferring or entrusting the management of their shares for 36 months from the date of the company's stock listing[160]. - The company will adhere to the regulations of the Shanghai Stock Exchange regarding share transfers by major shareholders[160]. - The company has established measures to avoid future competition with other enterprises controlled by its major shareholders[163]. - The company emphasizes compliance with relevant regulations from the Shanghai Stock Exchange regarding share transfers and management[162].

Financial Performance - Operating revenue for the first quarter was CNY 22,523,377.19, representing a 4.14% increase year-on-year[5] - Net profit attributable to shareholders was CNY -24,462,266.30, showing a significant increase in losses compared to CNY -13,468,831.25 in the same period last year[5] - The company reported a net loss of CNY -136,646,152.90, compared to a loss of CNY -117,172,394.60 in the previous period[34] - Net profit loss for the first quarter was RMB 25,042,478.69, widening the loss by RMB 1,106,91 compared to the same period last year[27] - Total operating revenue for Q1 2021 was ¥22,523,377.19, an increase of 4.15% compared to ¥21,628,802.33 in Q1 2020[40] - Net loss for Q1 2021 was ¥25,042,478.69, compared to a net loss of ¥13,973,333.53 in Q1 2020, representing an increase in loss of 79.00%[41] - Comprehensive loss for Q1 2021 totaled ¥31,356,753.58, compared to a comprehensive loss of ¥18,397,477.63 in Q1 2020[42] - Total comprehensive income attributable to shareholders of the parent company was -¥28,250,831.23 in Q1 2021, compared to -¥17,892,975.35 in Q1 2020[42] Research and Development - Research and development expenses accounted for 109.36% of operating revenue, an increase of 43.02 percentage points from the previous year[5] - R&D expenses grew by 71.68% to RMB 24,632,032.55, driven by an increase in R&D personnel[21] - Research and development expenses rose to ¥24,632,032.55 in Q1 2021, a significant increase of 72.00% from ¥14,347,946.75 in Q1 2020[40] Cash Flow - The company reported a net cash flow from operating activities of CNY -10,322,097.52, an improvement from CNY -59,753,722.13 in the previous year[5] - The net cash flow from operating activities increased by RMB 49,431,600, attributed to higher cash receipts from sales and increased government subsidies[28] - The net cash flow from operating activities for Q1 2021 was -40,581,659.77 RMB, compared to -52,590,482.40 RMB in Q1 2020, showing an improvement of approximately 23%[48] - Total cash inflow from investment activities was 231,791,780.83 RMB, while cash outflow was 28,346,644.00 RMB, resulting in a net cash flow of 203,445,136.83 RMB, compared to -73,816,008.95 RMB in the previous year[49] Assets and Liabilities - Total assets increased by 6.52% to CNY 1,192,259,662.30 compared to the end of the previous year[5] - Total liabilities reached CNY 186,820,747.06, up from CNY 92,729,036.15, marking an increase of around 101%[34] - Current liabilities rose to CNY 88,103,321.07 from CNY 80,568,899.38, reflecting an increase of approximately 18.9%[34] - Non-current assets totaled CNY 402,957,729.56, compared to CNY 324,959,236.37, indicating a significant increase of about 24%[33] - Total assets amounted to CNY 1,119,280,166.10, a decrease of CNY 29,905,754.90 compared to the previous period[51] - Current assets totaled CNY 794,320,929.73, reflecting a decrease of CNY 643,337.76 from the prior period[51] - Total non-current assets amounted to approximately $405.61 million, with long-term equity investments at $266.96 million and other equity investments at $82.84 million[56] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,198[10] - The largest shareholder, Zhang Songgen, held 18.08% of the shares, totaling 75,664,000 shares[10] - The company’s total liabilities and equity amounted to CNY 1,192,259,662.30, consistent with total assets, reflecting a balanced financial position[34] Other Financial Metrics - Basic and diluted earnings per share were both CNY -0.06, compared to CNY -0.04 in the previous year[5] - The weighted average return on equity was -2.48%, slightly lower than -2.31% in the same period last year[5] - The company recorded non-recurring gains of CNY 4,728,186.18 during the reporting period[9] - Deferred income surged by 709.77% to RMB 33,598,233.33, mainly due to government grants received that have not yet met the conditions for recognition[20]

Financial Performance - The company reported a total revenue of RMB 100 million for the year 2020, marking a year-on-year increase of 20%[12]. - The company's operating revenue for 2020 was CNY 135,909,532.98, a decrease of 40.80% compared to the previous year[19]. - The net profit attributable to shareholders was a loss of CNY 54,470,877.18, which represents an increase in loss of 75.95% year-on-year[21]. - The net cash flow from operating activities decreased by 380.43% to CNY -57,578,159.36, primarily due to a decline in sales revenue[21]. - The total expenses for the period were CNY 20,920.98 million, a decrease of 19.78% compared to the previous year[21]. - The company achieved operating revenue of CNY 135.91 million, a year-on-year decrease of 40.80%[84]. - The net profit loss was CNY 54.17 million, an increase in loss of 58.53% year-on-year[84]. - The company's main business revenue in the medical device sector was CNY 126.88 million, with a year-on-year decrease of 43.47%[108]. - The orthopedic surgical navigation robot generated sales revenue of CNY 111.59 million, accounting for 87.95% of the main business revenue, with a year-on-year decrease of 47.74%[108]. Research and Development - The company is investing RMB 20 million in R&D for new technologies aimed at enhancing product efficiency[12]. - Research and development expenses accounted for 54.53% of operating revenue, an increase of 20.98 percentage points from the previous year[20]. - The total R&D investment for the year was approximately ¥74.11 million, a decrease of 3.76% compared to the previous year, while the R&D investment as a percentage of operating revenue increased by 20.98 percentage points to 54.53%[66]. - The company has submitted 72 new patent applications during the reporting period, including 30 invention patents, and has obtained 50 new patent authorizations, with 6 being invention patents[62]. - The company has developed high-precision online calibration technology for surgical robots, with an error requirement of less than 0.5 mm[47]. - The company has achieved significant advancements in the development of core components for the orthopedic surgical robot, including the medical robot-specific manipulator and optical tracking camera[63]. - The company has developed a modular design technology for surgical tools, enabling the orthopedic surgical robot to perform over ten different surgical procedures, with ongoing expansion[55]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2023[12]. - The company aims to reshape orthopedic surgical processes through intelligent methods, integrating all relevant technological elements into a smart orthopedic platform[33]. - The company is focused on establishing orthopedic surgical robot minimally invasive surgery centers in collaboration with medical institutions[149]. - The company plans to continue promoting its products in the Huazhong and Southwest regions, where revenue has seen some growth due to channel expansion efforts[110]. - The company is exploring partnerships to enhance distribution channels, aiming for a 25% increase in reach by the end of the next fiscal year[159]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy of its financial statements[5]. - There are no plans for profit distribution or capital increase through reserves for the reporting period[5]. - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing[157]. - The company will adhere to the regulations set forth by the China Securities Regulatory Commission regarding share rights and interests adjustments[157]. - The company has established a commitment to bear any economic liabilities related to employee social insurance contributions prior to its IPO[161]. Customer Engagement and Satisfaction - User data showed a growth of 25% in active users year-over-year, indicating strong customer engagement[159]. - Customer satisfaction ratings improved by 15%, indicating successful implementation of new service strategies[158]. Financial Management and Investments - The company raised a total of 100 million RMB through structured deposits from fundraising sources[184]. - The company has a strategy focused on diversifying its investment portfolio through various financial instruments[186]. - The company is actively managing its financial products to optimize returns and liquidity[185]. - The company has committed to strengthening the management of raised funds to prevent usage risks[163]. Social Responsibility - The company donated 100,000 RMB to support medical institutions in Hubei for purchasing epidemic prevention materials during the COVID-19 outbreak[198]. - The company contributed 200,000 RMB to assist in poverty alleviation efforts in Yushu Prefecture, Qinghai Province[198]. - The company invested 3 million RMB in the "Beijing Natural Science Fund - Haidian Original Innovation Joint Fund" to support key projects in the smart orthopedic field[198].

Financial Performance - Operating revenue for the first nine months decreased by 1.24% to CNY 76,443,945.53 compared to the same period last year[6] - Net profit attributable to shareholders was a loss of CNY 51,221,640.23, an improvement from a loss of CNY 82,346,697.79 in the same period last year[6] - The company reported a net cash flow from operating activities of -CNY 113,019,150.56 for the first nine months, compared to -CNY 43,697,340.43 in the same period last year[6] - The company expects a decline in sales in Q4 2020 compared to the previous year due to the impact of the COVID-19 pandemic, with anticipated losses for the full year expected to widen compared to 2019[21] - The company reported a net loss of ¥85,522,559.16 for Q3 2020, worsening from a loss of ¥48,656,884.36 in Q3 2019[31] - The total profit (loss) for Q3 2020 was reported at ¥-19,792,844.18, which is an improvement from ¥-26,812,956.11 in Q3 2019, indicating a reduction in losses by approximately 26.1%[39] - The company's total comprehensive loss for Q3 2020 was ¥-19,140,798.85, compared to ¥-23,443,897.79 in Q3 2019, marking a reduction of approximately 18.5%[36] Assets and Liabilities - Total assets increased by 53.78% to CNY 1,097,400,816.11 compared to the end of the previous year[6] - The company's total liabilities decreased to 74,480,336.71 RMB from 117,257,687.68 RMB year-on-year[26] - The total equity increased to 1,022,920,479.40 RMB from 596,344,353.97 RMB at the end of 2019, reflecting a significant growth in capital reserves[27] - Total current assets increased to ¥725,157,684.19 in Q3 2020, up from ¥493,510,149.21 in Q3 2019, representing a growth of approximately 47.0%[30] - The total liabilities decreased to ¥66,494,139.46 in Q3 2020 from ¥104,469,456.96 in Q3 2019, a reduction of approximately 36.4%[31] - The company reported a total asset value of 715,990,691.66[51] Shareholder Information - The total number of shareholders reached 12,095 by the end of the reporting period[11] - The largest shareholder, Zhang Songgen, holds 18.08% of the shares, totaling 75,664,000 shares[11] Research and Development - Research and development expenses accounted for 55.77% of operating revenue, down from 71.41% in the previous year[7] - R&D expenses for the first three quarters of 2020 amounted to ¥42,633,472.36, compared to ¥55,269,433.91 in the same period of 2019, showing a decrease of about 22.9%[34] - Research and development expenses for Q3 2020 amounted to ¥10,704,683.73, down from ¥18,987,545.60 in Q3 2019, reflecting a decrease of about 43.5%[39] Cash Flow - The company's cash and cash equivalents increased by 186.50% to RMB 437,275,142.72, primarily due to the successful fundraising from the issuance of new shares[15] - The net cash flow from operating activities was -113,019,150.56 RMB, a decrease from -43,697,340.43 RMB in the same period last year, largely due to a decline in advance payments received[20] - The net cash flow from financing activities increased significantly to 474,746,812.88 RMB, driven by successful fundraising from the Sci-Tech Innovation Board listing[20] - The ending cash and cash equivalents balance for Q3 2020 was 437,275,142.72 RMB, up from 102,795,135.41 RMB in Q3 2019[43] - The company reported a significant increase in cash inflow from tax refunds, which rose to 7,517,292.65 RMB from 2,176,908.82 RMB in the previous year[44] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 21,789,833.60 for the first nine months, contributing to its financial performance[8] - Other income rose by 94.07%, mainly due to an increase in government subsidy income during the reporting period[19] - The company reported other income of ¥7,191,827.73 for Q3 2020, an increase from ¥4,938,716.36 in Q3 2019, representing a growth of about 45.7%[39] Investment Income - Investment income surged by 185.92% to RMB 12,981,521.24, compared to RMB 4,540,198.81 in the previous year[18] - Investment income surged by 185.92%, attributed to higher returns from recovered equity investments and bank wealth management products compared to the previous year[19] Changes in Accounting Policies - Contract liabilities increased significantly due to a change in accounting policy, reflecting the reclassification of advance payments[17] - The company reclassified 3,980,509.15 RMB from inventory to contract assets due to the new revenue recognition standards[48] - The company also reclassified 46,375,657.14 from advance receipts to contract liabilities[52]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2020, representing a year-on-year increase of 20%[19] - The company's operating revenue for the first half of the year reached ¥47,757,305.35, an increase of 7.13% compared to ¥44,578,533.58 in the same period last year[20] - The company reported a total revenue of 333 million RMB for the first half of 2020, with a net profit of approximately 31.07 million RMB[65] - The company reported a net profit of 36 million RMB for the first half of 2020, marking a 15% increase compared to the same period last year[113] - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q2 2023, representing a 25% year-over-year growth[118] - The company reported a total of RMB 42,185,334.58 in contract liabilities, indicating a new revenue recognition strategy[153] - The total revenue for the first half of 2020 was 564,266,442 RMB, showing a decrease of 38,183,113 RMB compared to the previous period[180] Profitability and Losses - The net profit attributable to shareholders was a loss of ¥34,066,671.52, improving from a loss of ¥59,662,208.81 in the previous year[20] - The company has not yet achieved profitability, which may adversely affect shareholder investment returns in the short term[86] - The company’s net loss for the first half of 2020 was CNY 61,220,485.61, compared to a net loss of CNY 80,884,522.98 in the first half of 2019, showing an improvement of approximately 24.4%[159] - The company reported a net loss of 32,609,490 RMB for the first half of 2020, compared to a profit in the same period last year[180] - The total comprehensive income for the first half of 2020 was a loss of CNY 39,049,192.42, compared to a loss of CNY 63,272,074.30 in the same period of 2019, reflecting a reduction of approximately 38.3%[161] Research and Development - Research and development expenses increased by 10% to RMB 15 million, reflecting the company's commitment to innovation[19] - Research and development expenses accounted for 65.05% of operating revenue, a decrease of 12.45 percentage points from 77.50%[21] - The company reported a total R&D investment of ¥31,065,254.86, which accounts for 65.05% of its operating revenue[61] - The company has developed a series of multimodal medical imaging preprocessing and fusion algorithms to enhance surgical planning and execution[46] - The company has received 22 patent authorizations and submitted 12 new patent applications during the reporting period, enhancing its intellectual property protection in orthopedic surgical robots[59] - The company has developed three generations of orthopedic surgical robots, achieving a unified value in technology, product, and commercial aspects[69] - The company’s R&D team includes 5 PhD holders and 41 Master’s degree holders, contributing to its innovation capabilities[68] Market Expansion and Strategy - The company plans to launch a new orthopedic surgical robot model, TiRobot®, by the end of 2020, aiming to capture a larger market share[19] - Future guidance estimates a revenue growth of 30% for the second half of 2020, driven by increased demand for medical technology[19] - The company is expanding its market presence in Southeast Asia, targeting a 15% market penetration by 2022[19] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[119] - A strategic acquisition of a local tech firm was announced, expected to enhance the company's product offerings and customer base[114] - The company is exploring potential mergers and acquisitions to expand its market presence and diversify its product offerings[175] Operational Efficiency - The company has implemented new strategies to enhance operational efficiency, resulting in a 5% reduction in operational costs[19] - The company has increased its investment in new technologies and products, enhancing its market expansion efforts despite challenges posed by the COVID-19 pandemic[77] - The company aims to reduce its carbon footprint by 40% by 2025, aligning with sustainability goals and market expectations[119] - The company plans to implement cost-cutting measures that are expected to save approximately 50 million annually, improving overall profitability[119] Cash Flow and Financial Position - The net cash flow from operating activities was a negative ¥72,594,433.09, compared to a negative ¥14,427,550.06 in the same period last year[20] - Cash and cash equivalents at the end of the period reached ¥554,822,914.69, a substantial increase from ¥175,681,519.55 in the previous year[96] - The company raised 468,117,920.00 RMB through financing activities in the first half of 2020, a significant increase from 5,000,000.00 RMB in the same period of 2019[167] - The ending cash and cash equivalents balance increased to 554,822,914.69 RMB in 2020 from 175,681,519.55 RMB in 2019, reflecting a growth of approximately 215.5%[167] - The total liabilities at the end of the reporting period were 376,542,648 RMB, reflecting a stable financial position despite the losses[183] Shareholder Commitments and Regulations - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing, which began on July 29, 2019[108] - The company will not reduce its holdings of pre-IPO shares during the first three complete fiscal years after the stock listing, and can only reduce up to 2% of its total shares in the fourth and fifth fiscal years[110] - The company will ensure that any stock incentive plans are linked to the execution of its return measures[126] - The company will publicly disclose reasons for any unfulfilled commitments and apologize to shareholders and the public[127] - The company will take personal responsibility for any unfulfilled commitments by its directors and senior management[127] User Growth and Engagement - User data indicates an increase in the number of active users to 50,000, a growth of 25% compared to the previous half-year[19] - User data showed a growth of 25% in active users, reaching a total of 1.5 million users by the end of June 2020[114] - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous quarter[120] - Customer satisfaction ratings improved to 85%, reflecting the effectiveness of recent service enhancements[120]